Omzet 2024 * | 72,54 mln. 67,62 mln. | Omzet 2025 * | 68,35 mln. 63,71 mln. | Marktkapitalisatie | 268 mln. 250 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -168 mln. -157 mln. | Nettowinst (verlies) 2025 * | -167 mln. -156 mln. | EV/omzet 2024 * | 2,11 x |
Nettoliquiditeiten 2024 * | 115 mln. 107 mln. | Nettoliquiditeiten 2025 * | 281 mln. 262 mln. | EV/omzet 2025 * | -0,19 x |
K/w-verhouding 2024 * |
-1,72
x | K/w-verhouding 2025 * |
-2,18
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,18% |
Recentste transcriptie over Nektar Therapeutics
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 71 | 01-01-07 |
Robert Chess
CHM | Chairman | 66 | 01-12-91 |
Sandra Gardiner
DFI | Director of Finance/CFO | 58 | 17-04-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
R. Scott Greer
BRD | Director/Board Member | 65 | 01-01-10 |
Roy A. Whitfield
BRD | Director/Board Member | 70 | 01-08-00 |
Robert Chess
CHM | Chairman | 66 | 01-12-91 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+26,47% | 664 mld. | |
+26,17% | 567 mld. | |
-6,33% | 354 mld. | |
+19,35% | 330 mld. | |
+4,23% | 286 mld. | |
+14,40% | 234 mld. | |
+4,98% | 199 mld. | |
-10,02% | 196 mld. | |
-4,04% | 148 mld. |